Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients

Publication type:
Journal article
Metadata:
Autoren
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000176141900023&DestLinkType=FullRecord&DestApp=WOS_CPL
Externe Identifier
  • Clarivate Analytics Document Solution ID: 561LJ
  • PubMed Identifier: 12060626
ISSN
1078-0432
Ausgabe der Veröffentlichung
6
Zeitschrift
CLINICAL CANCER RESEARCH
Paginierung
1843 - 1848
Datum der Veröffentlichung
2002
Status
Published
Titel
Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients
Sub types
  • Article
Ausgabe der Zeitschrift
8

Data source: Web of Science (Lite)

Other metadata sources:
Abstract
<h4>Purpose</h4>Non-small cell lung cancer (NSCLC) is usually associated with a poor prognosis. Some patients survive their disease, and the underlying molecular mechanisms are still poorly understood. The purpose of this investigation was to evaluate expression profiles of proteins determining the survival of NSCLC patients for 5 years.<h4>Experimental design</h4>The expression of 21 gene products was evaluated immunohistochemically in paraffinembedded primary NSCLCs from 216 patients. The data were correlated with the survival times of the patients (survival of more or less than 5 years) by means of chi(2) test and hierarchical cluster analysis.<h4>Results</h4>The relationships of patients' survival and 21 parameters were determined including oncogene and tumor suppressor products and proliferative, apoptotic, and angiogenic factors. FOS, P53, RAS, ERBB1, JUN, PCNA, cyclin A, FAS/CD95, and HIF-1beta revealed a correlation to survival. In a second step, these nine parameters were further analyzed by hierarchical cluster analyses of all patients, of stage III patients, and of patients with squamous cell lung carcinomas. We identified clusters with significantly more long-term survivors. The expression of FOS, JUN, ERBB1, and cyclin A or PCNA were decreased in carcinomas of patients with long-term survival.<h4>Conclusions</h4>The expression profile of these factors predicts a significantly better long-term outcome of NSCLC patients. This may have implications for the development of individualized therapy options in the future.
Addresses
  • German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
Autoren
eISSN
1557-3265
Externe Identifier
  • PubMed Identifier: 12060626
Open access
false
ISSN
1078-0432
Ausgabe der Veröffentlichung
6
Zeitschrift
Clinical cancer research : an official journal of the American Association for Cancer Research
Schlüsselwörter
  • Humans
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Neoplasm Proteins
  • Immunoenzyme Techniques
  • Survival Rate
  • Cluster Analysis
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Time Factors
  • Middle Aged
Sprache
eng
Medium
Print
Paginierung
1843 - 1848
Datum der Veröffentlichung
2002
Status
Published
Datum der Datenerfassung
2002
Titel
Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
8

Data source: Europe PubMed Central

Abstract
PURPOSE: Non-small cell lung cancer (NSCLC) is usually associated with a poor prognosis. Some patients survive their disease, and the underlying molecular mechanisms are still poorly understood. The purpose of this investigation was to evaluate expression profiles of proteins determining the survival of NSCLC patients for 5 years. EXPERIMENTAL DESIGN: The expression of 21 gene products was evaluated immunohistochemically in paraffinembedded primary NSCLCs from 216 patients. The data were correlated with the survival times of the patients (survival of more or less than 5 years) by means of chi(2) test and hierarchical cluster analysis. RESULTS: The relationships of patients' survival and 21 parameters were determined including oncogene and tumor suppressor products and proliferative, apoptotic, and angiogenic factors. FOS, P53, RAS, ERBB1, JUN, PCNA, cyclin A, FAS/CD95, and HIF-1beta revealed a correlation to survival. In a second step, these nine parameters were further analyzed by hierarchical cluster analyses of all patients, of stage III patients, and of patients with squamous cell lung carcinomas. We identified clusters with significantly more long-term survivors. The expression of FOS, JUN, ERBB1, and cyclin A or PCNA were decreased in carcinomas of patients with long-term survival. CONCLUSIONS: The expression profile of these factors predicts a significantly better long-term outcome of NSCLC patients. This may have implications for the development of individualized therapy options in the future.
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/12060626
ISSN
1078-0432
Ausgabe der Veröffentlichung
6
Zeitschrift
Clin Cancer Res
Schlüsselwörter
  • Carcinoma, Non-Small-Cell Lung
  • Cluster Analysis
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunoenzyme Techniques
  • Lung Neoplasms
  • Middle Aged
  • Neoplasm Proteins
  • Survival Rate
  • Time Factors
Sprache
eng
Country
United States
Paginierung
1843 - 1848
Datum der Veröffentlichung
2002
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2002
Titel
Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
8

Data source: PubMed

Beziehungen:
Property of

Tools